MolNFT v1 · #145156 · protein
Structure of human alpha-phosphomannomutase 1 containing mutations R180T and R183I
6CFT: “Structure of human alpha-phosphomannomutase 1 containing mutations R180T and R183I”. X-ray diffraction, 1 ligand (MG), 1 pocket (best druggability 0.60). MolNFT v1 #145156 on GenesisL1: 3D structure, binding sites and pockets in…
- PDB
- 6CFT
- Type
- protein
- Length
- 245 residues
- Chains
- 1
- Method
- x-ray diffraction
- Collection
- MolNFT v1 / PDB
- Contract
- 0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
- Owner
- 0x3396CDB397284571d12822B4ae1189a8E22AAAAA
- Molecule
- Phosphomannomutase 1
- EC
- 5.4.2.8
- UniProt
- Q92871
- Ligands
- MG
- Pockets
- 1 · best druggability 0.60
Structure
x-ray diffraction · 1 distinct chain · 40% helix, 20% strand (DSSP).
| Chain | Molecule | Type | Residues | Secondary structure | UniProt |
|---|---|---|---|---|---|
| A | Phosphomannomutase 1 (EC 5.4.2.8) | protein | 245 | 40% helix, 20% strand | Q92871 |
Ligands and binding sites
- MG · Magnesium ion · metal · 2 copies · chains A
Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.
Pockets
1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.
| Volume (ų) | Druggability | Buriedness | Lining residues | Inside | |
|---|---|---|---|---|---|
| 1 | 361 | 0.60 | 0.77 | 42 | MG |
Compared structures
- 6CFT · Structure of Human alpha-Phosphomannomutase 1 containing mutations R180T and R183I · the same entry in another collection · chain A against A, TM-score 1.00
- Q92871 · AlphaFold monomer V2.0 prediction for phosphomannomutase 1 (Q92871) · a predicted model of the same protein · chain A against A, TM-score 0.92
Analyse
- Open in the research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides and crosslinks on the 3D structure
- Every structure of UniProt Q92871
- Elsewhere: RCSB PDB 6CFT · PDBe 6CFT · UniProt Q92871
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.